02 July, 2017
In terms of Buy, Sell or Hold recommendations, Conatus Pharmaceutic (NASDAQ:CNAT) has analysts' mean recommendation of 1.7. Renaissance Technologies LLC boosted its stake in Conatus Pharmaceuticals by 28.1% in the first quarter. Geode Capital Management LLC boosted its stake in shares of Conatus Pharmaceuticals by 21.4% in the first quarter. Aegis restated a "buy" rating and issued a $11.00 price objective on shares of Conatus Pharmaceuticals in a report on Monday, May 15th. Susquehanna Group Incorporated Limited Liability Partnership reported 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT).
Conatus Pharmaceuticals Inc. (CNAT) surprised the stock market in its last reported earnings when it earned -$0.14 a piece versus the consensus-estimated -$0.22. The company has a 50-day moving average price of $5.22 and a 200-day moving average price of $5.27. Finally, Zacks Investment Research raised shares of Conatus Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, March 14th. The firm had revenue of $7 million for the quarter, compared to analyst estimates of $5.88 million. Conatus Pharmaceuticals Inc. (CNAT) has made its way to a 12-month gain of 175.86%.
As of this writing, all the 7 analysts polled in the past 12 months rate Conatus stock a Buy. Vanguard Group Inc. raised its position in shares of Conatus Pharmaceuticals by 93.1% in the first quarter. Geode Capital Management LLC now owns 104,972 shares of the biotechnology company's stock worth $605,000 after buying an additional 18,512 shares in the last quarter. Important factors to focus when evaluating a stock's present and future value are the 52 week price high and low levels. On Friday, July 1 the stock rating was initiated by Roth Capital with "Buy". Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company's stock valued at $464,000 after buying an additional 1,655 shares in the last quarter. Stifel Nicolaus reaffirmed a "buy" rating and set a $9.00 price objective (up from $7.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, March 16th. Finally, Morgan Stanley raised its stake in shares of Conatus Pharmaceuticals by 265.6% in the first quarter. Its book value per share for the most recent quarter is $0.74 while its price to book ratio for the same period is 8.38, as for as the company's cash per share for the most recent quarter is $2.68, however its price to cash per share ratio for the same period is 2.31. Analysts are forecasting earnings of $-0.09 on a per share basis this quarter. In comparison, previous year the company earned revenue of $0 and had a GAAP net loss of $6.47 million. The company's market cap is $146.55 million.
Conatus Pharmaceuticals Inc. (CNAT) now has P/E (Price to Earnings) ratio of 0 while the company's industry has 229.11 P/E and the sector P/E is 18.75. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & worldwide copyright & trademark law. California-based Blackrock Institutional Trust Communication Na has invested 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). The correct version of this news story can be accessed at https://www.thestockobserver.com/2017/07/01/conatus-pharmaceuticals-inc-cnat-position-held-by-united-capital-financial-advisers-llc-updated.html. It focuses in development of Emricasan, orally active protease inhibitor created to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease. Taking a look back at some historical performance numbers for Conatus Pharmaceuticals Inc. The Company operates through commercialization and development of pharmaceutical products segment.